TAIRX, INC.
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.trx.com.tw
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of TRX-920 for Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TRX-920 Oral Gel (10 mg and 30 mg)
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06143774
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
- Conditions
- Advanced CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05257590
- Locations
- 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
- Conditions
- Advanced Cancer
- Interventions
- Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04336124
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
- Conditions
- Lung Neuroendocrine NeoplasmNeuroendocrine CarcinomaPancreatic Neuroendocrine TumorNeuroendocrine TumorsGastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03600233
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇨🇳New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaAdvanced Cancer
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03582618
- Locations
- 🇺🇸
Charleston Hematology Oncology Associates, Charleston, South Carolina, United States
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next